Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 11/20 | 0.61 |
| ▸ | NPBWR1 | P48145 | 9/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30401893 | 0.95 | NPBWR1 (0.63) | KISS1RNPBWR1 | |
| SCHEMBL31247913 | 0.92 | NPBWR1 (0.57) | KISS1RNPBWR1 | |
| SCHEMBL29825066 | 0.91 | NPY4R (0.61) | KISS1RNPBWR1 | |
| SCHEMBL29794137 | 0.91 | GHSR (0.57) | KISS1RNPBWR1 | |
| SCHEMBL30402141 | 0.90 | NPBWR1 (0.58) | KISS1RNPBWR1 | |
| SCHEMBL29483770 | 0.89 | GHSR (0.60) | NPBWR1 | |
| SCHEMBL29483769 | 0.89 | GHSR (0.60) | NPBWR1 | |
| SCHEMBL29641173 | 0.89 | GHSR (0.60) | NPBWR1 | |
| SCHEMBL2183733 | 0.88 | NPBWR1 (0.54) | KISS1RNPBWR1 | |
| SCHEMBL31018702 | 0.88 | IL23R (0.58) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4392440-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | River 2 Renal Corp. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
| WO-2023028008-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | RIVER 2 RENAL CORP. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | KISS1R 1311/4885NPBWR1 56/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | KISS1R 301/4885NPBWR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.